| abstract |
The invention relates to the 1,2,5 benzothiadiazepine derivatives of the formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport inhibitory activity (LBAT). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and disorders due to the use of glucose, gastrointestinal diseases and liver diseases. |